Philippine GDP Growth Slows to 2.3% in Q2 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
Gold Prices Surge 7% as Dollar Falls, Fed Rate Hike Bets Ease 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
China Exports Beat July Forecasts as AI Demand Fuels High-Tech Trade 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls 
Asian Stocks Cautious Ahead of US Jobs Data as Oil Rises 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
